



Published in final edited form as:

Nature. 2018 March 08; 555(7695): 269–273. doi:10.1038/nature25758.

STRUCTURE OF THE D₂ DOPAMINE RECEPTOR BOUND TO THE ATYPICAL ANTIPSYCHOTIC DRUG RISPERIDONE

Sheng Wang^{1,§}, Tao Che¹, Anat Levit², Brian K. Shoichet², Daniel Wacker^{1,§}, and Bryan L. Roth^{1,3,4,§}

¹Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599-7365, USA

²Department of Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, 94158-2280, USA

³Division of Chemical Biology & Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7360, USA

⁴National Institute of Mental Health Psychoactive Drug Screening Program (NIMH PDSP), School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7365, USA

Summary

Dopamine is a neurotransmitter that has been implicated in processes as diverse as reward, addiction, control of coordinated movement, metabolism and hormonal secretion. Correspondingly, dysregulation of the dopaminergic system has been implicated in diseases ranging from schizophrenia, Parkinson's disease, depression, attention deficit hyperactivity disorder, nausea and vomiting, among others. Dopamine's actions are mediated by a family of five G-protein coupled receptors (GPCRs) (viz. D₁, D₂, D₃, D₄ and D₅)¹. The D₂ dopamine receptor (DRD2) is the primary target for both typical² and atypical^{3,4} antipsychotic drugs, and for Parkinson's disease drugs. Unfortunately, many drugs targeting DRD2 frequently suffer from serious and potentially life-threatening side effects due to promiscuous activities against related receptors^{4,5}. Accordingly, a molecular understanding of DRD2 structure and function could

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms Reprints and permissions information is available at www.nature.com/reprints.

[§]Correspondence to: shengunc@email.unc.edu (S.W.); dwacker@email.unc.edu (D.W.); bryan_roth@med.unc.edu (B.L.R.).

Author Contributions

S.W. designed experiments, developed the DRD2 construct and purification; expressed, purified and crystallized the receptor; collected diffraction data; solved and refined the structure; analyzed the structure, performed radioligand binding, and prepared the manuscript. T.C. performed radioligand binding, analyzed the data, and assisted with preparing the manuscript. A.L. conducted the homology modeling and docking and helped edit the manuscript. B.K.S. supervised the modeling and docking and helped prepare the manuscript. D.W. refined and analyzed the structure, supervised the structure determination and assisted with preparing the manuscript. B.L.R. supervised the overall project and management and prepared the manuscript.

Author Information

Atomic coordinates and structure factors for the reported crystal structure have been deposited in the PDB under accession 6C38. Readers are welcome to comment on the online version of the paper. Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The authors declare no competing financial interests.

provide a template for the design of safer and more effective medications. Here we provide the crystal structure of DRD2 in complex with the widely prescribed atypical antipsychotic drug risperidone. The DRD2-risperidone structure reveals an unexpected mode of antipsychotic drug binding to dopamine receptors, and illuminates structural determinants essential for the actions of risperidone and related drugs at DRD2.

The D₂ dopamine receptor (DRD2) is essential for mediating the actions of antipsychotic drugs^{2,3,4,6}, and also for medications used to treat Parkinson's disease, hyperprolactinemia, nausea and vomiting, among many other disorders^{1,7,8}. DRD2 has also been implicated in the actions of several drugs of abuse including amphetamines, cocaine and opioids⁹. Although DRD2 was cloned nearly 30 years ago^{10,11,12} and has been subject to extensive pharmacological¹³, mutagenesis¹⁴ and molecular modeling studies¹⁵, we lack high resolution structures of DRD2 in complex with ligands, impeding a molecular understanding of the receptor's function. Meanwhile, a 3.2 Å crystal structure of the related D₃ dopamine (DRD3) was reported 7 years ago¹⁶ while 1.95 and 2.2 Å structures of the D₄ dopamine (DRD4) receptors have been more recently reported¹⁷. The DRD3 and DRD4 ligand complexes—obtained with the substituted benzamides eticlopride and nemonapride, respectively—revealed distinctive extended binding sites^{16,17}. Given the importance of DRD2-targeted drugs, and recent successes in leveraging GPCR structures for the structure-guided discovery of new probes and drug-leads^{18,19}, the structure of a DRD2 complexed with non-benzamides ligands will not only clarify the specificity determinants of the family, but will also expand our understanding of how different scaffolds interact with dopamine receptors. We anticipate that the ligand discovery enabled by DRD2 structures would thus inform both basic and translational neuroscience²⁰.

Structural studies were carried out using an engineered human DRD2 construct, which included three thermostabilizing mutations (I122^{3.40}A, L375^{6.37}A and L379^{6.41}A), and T4 lysozyme (T4L) fused into intracellular loop 3 (Extended Data Figs. 1a-b and METHODS). This construct was purified and crystallized in complex with the atypical antipsychotic risperidone. The binding affinities of multiple antipsychotics were similar with this DRD2 construct versus the wild-type receptor (Extended Data Table 1), suggesting that the engineered alterations which facilitate crystallization do not perturb ligand binding. The crystal structure of the DRD2/risperidone complex was determined at 2.9 Å resolution (Extended Data Table 2 and Extended Data Figs. 1c-h).

Compared with DRD4 (PDB codes: 5WIU and 5WIV) and DRD3 (PDB code: 3PBL), DRD2 displays substantial structural differences in extracellular loops 1 and 2 (EL₁ and EL₂) and the extracellular ends of Transmembrane helices (TM) V, VI and VII (Figs. 1a-c). Unexpectedly, the largest extracellular loop of DRD2—EL₂—flips away from the top of the receptor core (Fig. 1c) when compared with DRD3 and DRD4. Importantly, the highly conserved hydrophobic residue of EL₂, which is two residues away from the conserved cysteine of EL₂ in all extant aminergic GPCR structures and is represented by Ile184 in DRD2, points towards the receptor core (Extended Data Fig. 2). This residue has been implicated in the on- and off-rate kinetics and in β-arrestin biased signaling for some ligands at DRD2 and other receptors^{19,20,21}. However, because of the rearrangement of EL₂ and its

formation of a small helical turn (residues 182–185) in the DRD2/risperidone structure (Fig. 1c and Extended Data Fig. 2c), Ile184 does not directly interact with this ligand, as does the analogous residue in some aminergic structures (Extended Data Figs. 2a-l). Instead, Ile184 points across the binding pocket to interact with Trp100 in EL₁, forming a network of hydrophobic residues near the binding pocket's orifice (Extended Data Fig. 2m). We note that interactions between T4L with part of EL₁ and EL₂ in the crystal lattice may further stabilize this conformation (Extended Data Figs. 1c-e). While crystal contacts may influence sidechain rotamers on protein surfaces, their low binding energies are unlikely to induce the observed conformation.

Another difference observed between DRD2 and the other two D₂-like dopamine receptors is that the extracellular tip of TM V is shifted towards the transmembrane bundle, while the extracellular tips of TM VI and TM VII move away from the receptor core by approximately 5.8/7.3 Å and 1.4/2.1 Å (Fig. 1b), respectively, versus DRD3 and DRD4. As in DRD3, an inter-helical hydrogen bond forms between Tyr^{7.35} and His^{6.55} (Extended Data Fig. 3a-d), which in DRD3 is important for regulating constitutive activity¹⁷. The side-chain conformations for DRD2, DRD3¹⁶ and DRD4¹⁷ at residues Tyr/Val^{7.35} and His^{6.55} (Extended Data Figs. 3a-c) are also distinct¹⁷. Specifically, the side chain of Tyr^{7.35} in DRD2 is rotated 52° compared to DRD3 to accommodate risperidone (Extended Data Fig. 3d). Together, these differences may further stabilize the outward movement of TM VI.

Like most antipsychotics, risperidone is a DRD2 inverse agonist²², and the DRD2/risperidone complex appropriately reflects an inactive state conformation. The most notable difference between active and inactive state GPCR structures is the extent to which the cytoplasmic tip of TM VI moves away from the transmembrane helical bundle to accommodate transducer binding²³. A comparison of DRD2/risperidone with the active and inactive β₂ adrenergic receptor (β₂AR) or adenosine A_{2A} receptor (A_{2A}AR) structures reveals no substantial outward movement of the intracellular end of TM VI (Extended Data Figs. 3e-f)—a finding consistent with an inactive-state structure. Another important structural feature of GPCR activation is the rearrangement of side chains in the highly conserved microswitches D(E)/RY (TM III) and NPxxY (TM VII)²³. Here, Tyr^{7.53} from the NPxxY motif and Arg^{3.50} from the DRY motif, adopt almost identical positions with homologous residues in the β₂AR and A_{2A}AR inactive structures (Extended Data Figs. 3g-j). Moreover, a key inactive-state salt-bridge interaction, the 'ionic lock' between the conserved Arg^{3.50} and Glu^{6.30}^{24,25,26} is maintained in the DRD2/risperidone structure (Fig. 1d).

Risperidone—a benzisoxazole²⁷—displays a unique mode of dopamine receptor binding versus those of the substituted benzamides eticlopride at DRD3 and nemonapride at DRD4 (Fig. 2). The benzisoxazole moiety of risperidone extends into a deep binding pocket defined by the side chains of helices III, V and VI (Figs. 2a and 2d), interacting with Cys118^{3.36}, Thr119^{3.37}, Ser197^{5.46}, Phe198^{5.47}, Phe382^{6.44}, Phe390^{6.52} and Trp386^{6.48} which form a subpocket below the orthosteric site (Fig. 2d). Additionally, another hydrophobic pocket above the orthosteric site encloses risperidone's tetrahydropyridopyrimidinone moiety while Asp114^{3.32} forms a salt-bridge with risperidone's tertiary amine (Fig. 2d). Alanine mutagenesis of many of these contact residues reduce risperidone's affinity at DRD2 (Fig. 2d and Extended Data Table 3). In the DRD3 and DRD4 structures, neither eticlopride nor

nemonapride engage this deeper hydrophobic pocket (Figs. 2b and 2c). Importantly, alanine substitutions of the equivalent residues in this deeper hydrophobic pocket do not substantially alter [³H]-nemonapride binding affinity, except for Trp386^{6.48} and Phe390^{6.52}, which are large enough that mutagenesis-induced alterations in helical packing alone might explain the observed effects (Extended Data Table 3).

Comparison of the overall ligand binding pocket of DRD2 with DRD3 and DRD4 structures revealed striking differences around residues Val/Phe^{2.61}, Trp^{EL1}, Phe/Leu^{3.28} and Tyr/Val^{7.35}, which help to define a DRD2 extended binding pocket (DRD2-EBP) (Figs. 3a and b). Indeed, previous studies^{16,17} on DRD3 and DRD4 revealed a selective EBP for each receptor. The DRD3-EBP is formed by the junction of EL₁ and EL₂ and the interface of helices II, III and VII and towards the EL₁ (Fig. 3c). While the DRD4-EBP is elsewhere, reaching deep into a cleft between TMs II and III in this receptor, defined by Phe91^{2.61}/Leu111^{3.28} (Fig. 3d); the structural definition of this DRD4-EBP enabled the structure-based discover of agonists highly specific for this receptor¹⁷. Unique to the DRD2, the DRD2-EBP extends toward the extracellular part of TM VII consisting of EL₁ and the junction of helices I, II and VII (Fig. 3b).

There are four distinctive features of the DRD2-EBP: (1) Compared with the DRD3 structure, part of the EL₁ loop rotates to move the conserved residue Trp^{EL1} to the top of the binding pocket at DRD2 (Figs. 3a-c and Extended Data Fig. 4), thereby disrupting what would be the DRD3-EBP (Figs. 3a-c). In all published aminergic receptor structures, only DRD2's Trp^{EL1} adopts this unique conformation (Extended Data Fig. 4). (2) Compared with the DRD4 structure, the residue phenylalanine is located at 3.28 of DRD2, not 2.61, thereby eliminating the extended pocket as it exists in DRD4 (Figs. 3a, b and d). (3) Meanwhile, the side chain of Tyr408^{7.35} rotates towards the side chain of His393^{6.55} thereby avoiding clashes with risperidone (Extended Data Figs. 3a and 3d). (4) Finally, an outward movement of the extracellular tip of TM VII (Fig. 1b) makes additional space for the DRD2-EBP.

Compared to the conformation risperidone adopts when crystalized by itself⁴, in complex with DRD2, risperidone's tetrahydropyridopyrimidinone ring rotates by ~90° (Extended Data Fig. 5a). This ring interacts with a hydrophobic patch formed by the side-chains of Trp100^{EL1}, Ile184^{EL2}, and Leu94^{2.64}. Although the electron density for Leu94^{2.64} is weaker than for the other residues, it appears that the observed conformation of Trp100^{EL1} is stabilized by any rotamer of Leu94^{2.64} that would fit the density.

In the DRD2/risperidone structure, the side chain of Trp100^{EL1} forms extensive contacts with the tetrahydropyridopyrimidinone ring, wedging it into the DRD2-EBP (Figs. 3b, 4a and Extended Data Fig. 5b). Besides these hydrophobic contacts between Trp100^{EL1} and risperidone, Trp100^{EL1} is also stabilized by contacts with Ile184^{EL2} and, perhaps Leu94^{2.64}, though the side-chain of Leu94^{2.64} lacks electron density (Fig. 4b and Extended Data Fig. 5c). The observed configuration of risperidone is likely driven by the DRD2 binding pocket, and the conservation of key pocket residues such as Trp100^{EL1} implies that risperidone could bind other aminergic receptors (e.g. 5-HT_{2A} or the α_{1A} adrenergic receptor) in a similar binding mode, though further structures will be needed to test this notion.

Intriguingly, molecular docking of risperidone to homology models of the DRD2, templated on either the DRD3 or DRD4 structures, failed to reproduce the unique pose of risperidone (Extended Data Figs. 5d-h). Rather, docking places the ligand higher in the binding site, in a space analogous to where both eticlopride and nemonapride are observed in the DRD3 and DRD4 structures (Figs. 2b-c), respectively. This is a direct consequence of the conformational rearrangements in DRD2 concomitant with accommodating risperidone—mainly movement of TMs V, VI, VII, and the relocation of Trp100^{EL1}, which consequently affects the size and shape of the ligand binding pocket, allowing risperidone to engage a deep binding pose and DRD2-EBP. Moreover, the docked conformation of risperidone resembles that of the receptor-free risperidone crystal structure⁴, not that adopted in the receptor-bound complex (Extended Data Figs. 5d-h). This is not a problem of conformational sampling on the part of docking—the receptor-free structure is, after all, a low energy structure, and docking does capture it, but rather it reflects the incorrect modeling of Trp100^{EL1}, owing to the lack of an analogous configuration in templates used in the modeling. Accordingly, docking did not predict the ~90° rotation of the tetrahydropyridopyrimidinone ring of risperidone in the DRD2-complex. This unique DRD2 binding pocket, and the unusual risperidone conformation that is accommodated by it, are unexpected features of this structure, with implications for our understanding of ligand recognition by this receptor, and the future design of new ligands to modulate it.

Compared with the DRD3 and DRD4 structures, the rearrangement of the extracellular surface and movement of Trp100^{EL1} not only allows it to interact with risperidone, but also forms, together with Ile184^{EL2} and Leu94^{2.64}, a hydrophobic patch that potentially narrows DRD2's binding pocket (Figs. 4b-c). We hypothesized that these residues prevent risperidone's egress from the binding pocket and found that Trp100^{EL1}Phe, Trp100^{EL1}Leu and Trp100^{EL1}Ala mutants decreased risperidone residence time from 233 min (WT) to 59, 23, 28 min (Table 1 and Extended Data Figs. 6a-d), respectively. Interestingly, these kinetic effects of the Trp100^{EL1}Phe, Trp100^{EL1}Leu and Trp100^{EL1}Ala mutants on residence time were shared with other tested antipsychotics, including N-methylspiperone, nemonapride and aripiprazole (Extended Data Figs. 6h-k and 6o-p and Extended Data Table 4). Similar to the findings obtained for the I184^{ECL2}A/L94^{2.64}A double mutation (Table 1 and Extended Data Fig. 6g), this double mutation also reduces risperidone residence time to 6 min, as it does for other antipsychotics (Table 1, Extended Data Figs. 6n, 6q and 6r and Extended Data Table 4). In summary, L94^{2.64}, Trp100^{EL1} and I184^{ECL2} form hydrophobic contacts which contribute to risperidone's slow DRD2 dissociation.

Among the most dramatic and serious side-effects of antipsychotics are extra pyramidal symptoms (EPS). In patients with EPS, a consistent finding is DRD2 occupancy > 80% in the central nervous system, as demonstrated by positron emission tomography (PET)²⁸. It has been suggested that differential binding kinetics^{29,30} as well as the relatively higher affinity of atypical antipsychotic drugs for 5-HT_{2A} serotonin receptors^{3,4}, contribute to the lower incidence of EPS with atypical antipsychotic drugs like risperidone versus typical antipsychotics. Relevant to these hypotheses we note that Trp100^{EL1} regulates both the association and dissociation kinetics for risperidone, and that many of the residues essential for risperidone binding to DRD2 are shared with 5-HT_{2A} serotonin and other biogenic amine receptors. Thus, although our findings do not definitively resolve these hypotheses,

they do provide the initial underpinnings for molecularly-derived models of antipsychotic drug actions at dopamine and other receptors. Finally, given recent successes in leveraging crystal structures of GPCRs for ligand discovery^{17,18,19}, we anticipate that the DRD2/risperidone complex structure will accelerate the search for novel antipsychotic drugs targeting DRD2.

Methods

Protein engineering for structural studies

To facilitate expression, purification and crystallography, a human DRD2 (D₂ long receptor variant³¹) construct was generated with several modifications. T4L residues 2–161³² were fused into third intracellular loop of DRD2 (V223–R361) with truncations of the N terminus residues 1–34. The DRD2-T4L gene was further modified by introducing three mutations I122^{3,40}A, L375^{6,37}A and L379^{6,41}A -identified by alanine scanning - to improve protein thermo-stability. In brief, alanine scanning was used to identify thermo-stabilization mutations (see Radioligand Binding Assay for details; Extended Data Fig. 1a). The receptor chimeric sequences were then subcloned into a modified pFastBac1 vector (Invitrogen), designated as pFastBac1-833100, which contained an expression cassette with a haemagglutinin (HA) signal sequence followed by a Flag tag, a 10×His tag, and a TEV protease recognition site at the N terminus before the receptor sequence.

Protein expression and purification

The modified DRD2-T4L protein was expressed in *Spodoptera frugiperda* (Sf9) cells (Expression Systems) using Bac-to-Bac Baculovirus Expression System (Invitrogen) for 48 h. The insect cells were lysed by repeated washing and centrifugation, with hypotonic buffer with low (10 mM HEPES, pH 7.5, 10 mM MgCl₂, 20 mM KCl and EDTA-free complete protease inhibitor cocktail tablets (Roche)) (one time) and high salt (1.0 M NaCl, 10 mM HEPES, pH 7.5, 10 mM MgCl₂, 20 mM KCl) (three times). The washed membranes were suspended in buffer containing 10 mM HEPES, pH 7.5, 10 mM MgCl₂, 20 mM KCl, 150 mM NaCl, 20 μM risperidone, and EDTA-free complete protease inhibitor cocktail tablets, and incubated at room temperature for 1 h. And, incubated at 4 °C for 30 min before solubilization. The membranes were then solubilized in 10 mM HEPES, pH 7.5, 150 mM NaCl, 1% (w/v) n-dodecyl-β-D-maltopyranoside (DDM, Anatrace), 0.2% (w/v) cholesteryl hemisuccinate (CHS, Sigma) for 2 hr at 4 °C.

The supernatant was isolated by centrifugation at 150,000 × g for 30 min, followed by incubation in 20 mM buffered imidazole (pH 7.5), 800 mM NaCl with TALON IMAC resin (Clontech) at 4 °C, overnight. The resin was then washed with 10 column volumes (cv) of Wash Buffer I (50 mM HEPES, pH 7.5, 800 mM NaCl, 0.1% (w/v) DDM, 0.02% (w/v) CHS, 20 mM imidazole, 10% (v/v) glycerol, and 10 μM risperidone, followed by 10 cv of Wash Buffer II (25 mM HEPES, pH 7.5, 150 mM NaCl, 0.05% (w/v) DDM, 0.01% (w/v) CHS, 10% (v/v) glycerol, and 10 μM risperidone). The protein was then eluted in 3–4 column volumes of Elution Buffer (50 mM HEPES (pH 7.5), 50 μM risperidone, 500 mM NaCl, 10% (v/v) glycerol, 0.05% (w/v) DDM, 0.01% (w/v) CHS, and 250 mM imidazole). A PD MiniTrap G-25 column (GE Healthcare) was used to remove imidazole. The protein

was then treated overnight with His-tagged TEV protease and His-tagged PNGase F (NEB) to remove the N-terminal His-tag, Flag-tag and deglycosylate the receptor. His-tagged TEV protease, His-tagged PNGase F, cleaved His-tag and uncleaved protein were removed from the sample by passing the sample over equilibrated TALON IMAC resin (Clontech). The receptor was then concentrated to 40–50 mg ml⁻¹ with a 100 kDa molecular mass cut-off Vivaspin 500 centrifuge concentrator (Sartorius Stedim).

Lipidic cubic phase crystallization

Protein samples of DRD2 in complex with risperidone were reconstituted into the lipidic cubic phase (LCP) by mixing 40% of ~60 mg/ml with 60% lipid (10% (w/w) cholesterol, 90% (w/w) monoolein) using the twin-syringe method³³. Crystallization trials were performed in glass sandwich plates (Marienfeld GmbH) using a handheld dispenser (Art Robbins Instruments), dispensing 45 nL of protein-laden LCP and 1 µl precipitant solution per well. Plates were then incubated at 20 °C. Crystals were obtained from precipitant conditions containing 100 mM Tris/HCl pH 7.8, 230 mM Lithium nitrate, 25% PEG400, 4% (±)-1,3-Butanediol. Crystals grew to maximum size of 40 µm × 40 µm × 10 µm within two weeks and were harvested directly from the LCP matrix using MiTeGen micromount and flash frozen in liquid nitrogen.

Data collection, structure solution and refinement

Crystallographic diffraction data collection were performed at the 23ID-B and 23ID-D beamlines (GM/CA CAT) at the Advanced Photon Source, Argonne, IL using a 10 µm minibeam at a wavelength of 1.0330 Å and a Dectris Eiger-16m or MarMosaic 300 CCD or Pilatus3 6M detector, respectively. The crystals were exposed to 0.5 s of unattenuated beam using 0.5° oscillation per frame. A 97.3 % complete data set at 2.90 Å resolution of DRD2/risperidone from 20 crystals were integrated, scaled and merged using HKL3000³⁴. Initial phase information was obtained by molecular replacement (MR) with the program PHASER³⁵ using two independent search models - a receptor portion of the DRD4/nemonapride complex (PDB code: 5WIU), and the T4L portions of β2AR-T4L (PDB code: 2RH1) as initial models. Refinement was performed with PHENIX³⁶ and REFMAC followed by manual examination and rebuilding of the refined coordinates in the program COOT³⁷ using $|2F_o| - |F_c|$, $|F_o| - |F_c|$, and omit maps.

Radioligand Binding Assay

Binding assays were performed using Sf9 membrane fractions expressing the crystallization construct DRD2-T4L (I122^{3.40A}, L375^{6.37A} and L379^{6.41A}) or HEK293 T membrane preparations transiently expressing DRD2 (D₂ long receptor) and different mutants. HEK293 T cells (ATCC CRL-11268; 59587035; mycoplasma free) were transfected and membrane preparation and radioligand binding assays were set up in 96-well plates as described previously³⁸. All binding assays were conducted in standard binding buffer (50 mM Tris, 10 mM MgCl₂, 0.1 mM EDTA, 0.1% BSA, pH 7.4). For displacement experiments, increasing concentrations of compounds were incubated with membrane and radioligands (0.8–1.0 nM [³H]-N-methylspiperone or 0.1–0.5 nM [³H]-nemonapride) (PerkinElmer) for 2 hr at room temperature in the dark. To determine the affinity of nemonapride in DRD2 and different mutants, all assays utilized at least 2 concentrations of

[³H]-nemonapride. The reaction was terminated by rapid vacuum filtration onto chilled 0.3% PEI-soaked GF/A filters followed by three quick washes with cold washing buffer (50 mM Tris HCl, pH 7.4) and quantified as described previously⁸. Results (with or without normalization) were analyzed using GraphPad Prism using one-site shift models where indicated.

Radioligand Based Thermostability Assay

Membranes from HEK293 T cells expressing wild-type or mutant human DRD2 were resuspended in binding buffer (50 mM Tris, 10 mM MgCl₂, 0.1 mM EDTA, 0.1% BSA, pH 7.4). [³H]-N-methylspiperone added to the membranes to give a final concentration of 1 nM. The samples were incubated at room temperature for 1 hr, then were aliquoted into PCR strips. Samples were heated to the desired temperature for exactly 30 min, then cooled down to 25 °C for 30 min. The samples were terminated by rapid vacuum filtration onto chilled 0.3% PEI-soaked GF/A filters followed by three quick washes with cold washing buffer (50 mM Tris HCl, pH 7.4) and quantified as described previously⁸. Results were analyzed using GraphPad Prism. Apparent T_m values were derived from sigmoidal dose–response analysis. Results represent the mean ± SEM of three independent experiments.

Differential Scanning Fluorimetry Based Thermostability Assay

The thermal stability of purified protein was determined by measuring fluorescence of thiol-reactive dye BODIPY FL-L-cystine (Invitrogen). The standard assay conditions were 20 mM HEPES (pH 7.5), 200 mM NaCl, 0.025% DDM and 10 mM risperidone with protein concentrations 1 mg/mL and BODIPY FL-L-cystine concentrations 1 μM. The melting experiments were performed on a StepOnePlus real-time PCR System from Applied Biosystems. The melting curve experiments were conducted (1 °C/min) and recorded using StepOne software from Applied Biosystems. Results were analyzed using GraphPad Prism. Apparent T_m values were derived from sigmoidal dose–response analysis. Results represent the mean ± SEM of three independent experiments.

Ligand Association and Dissociation Radioligand Binding Assays

Binding assays were performed using HEK293 T membrane preparations transiently expressing DRD2 (D₂ long receptor) and different mutants at room temperature. Radioligand dissociation and association assays were performed in parallel utilizing the same concentrations of radioligand, membrane preparations, and binding buffer (50 mM Tris, 10 mM MgCl₂, 0.1 mM EDTA, 0.1% BSA, pH 7.4). All assays utilized at least 2 concentrations of radioligand ([0.5–1.0 nM [³H]-N-methylspiperone; 0.5–2.0 nM [³H]-nemonapride). For dissociation assays, membranes were incubated with radioligand for at least 2 hr at room temperature before the addition of 10 μL of 10 μM excess cold ligand to the 200 μL membrane suspension at designated time points. For association experiments, 100 μL of radioligand was added to 100 μL membrane suspensions at designated time points. Time points spanned 1 minutes to 7 hr, depending on experimental conditions and radioligand. For the determination of k_{on} and k_{off} for unlabeled risperidone or aripiprazole, membranes of either wild type or mutants were incubated with [³H]-methylspiperone and several concentrations of risperidone or aripiprazole. Non-specific binding was determined by addition of 10 μM nemonapride. Immediately at time = 0 min, plates were harvested by

vacuum filtration onto 0.3% polyethyleneimine pre-soaked 96-well filter mats (Perkin Elmer) using a 96-well Filtermate harvester, followed by three washes of cold wash buffer (50 mM Tris pH 7.4). Scintillation cocktail (Meltilex, Perkin Elmer) was melted onto dried filters and radioactivity was counted using a Wallac Trilux MicroBeta counter (PerkinElmer). Data were analyzed using “Dissociation-One phase exponential decay” or “Association kinetics-Two or more concentrations of hot radioligand” in Graphpad Prism 5.0. The previously determined [³H]-N-methylspiperone k_{on} and k_{off} rates of DRD2 or mutants was used to estimate the k_{on} and k_{off} rates of risperidone and aripiprazole using the “Kinetics of competitive binding” equation in Graphpad Prism 5.0 as put forth by Motulsky and Mahan³⁹.

Homology modeling of DRD2

Sequence alignment for construction of the DRD2 homology models was generated with PROMALS3D⁴⁰, using sequences of human DRD2 (Uniprot accession number: P14416), DRD3 (P35462) and DRD4 (P21917), as well as sequences of available DRD2-family X-ray structures [DRD3 - PDB: 3PBL (chain A)⁴¹ and DRD4 - 5WIU (chain A)⁴²]. The alignment was manually edited to remove the amino and carboxy termini which extended past the template structures, and to remove the engineered T4 lysozyme (3PBL) or apocytochrome b562 RIL (BRIL; 5WIU) from the template sequences. MODELLER-9v15⁴³ was then used to generate (1) a total of 1000 homology models of DRD2, based on the crystal structure of DRD4 in complex with Nemonapride as the template, and (2) a set of 500 models based on the crystal structure of DRD3 in complex with Eticlopride. We then evaluated the models for their ability to enrich known DRD2 ligands over property-matched decoys through docking to the orthosteric binding site, using DOCK 3.7⁴⁴ (as detailed below). While sharing physical properties of known ligands, decoy molecules are topologically distinct and so unlikely to bind the receptor, thus controlling for the enrichment of molecules by physical properties alone. Thirty-two known DRD2 antagonists with MW < 420 were extracted from the IUPHAR database⁴⁵, and 1836 property-matched decoys were generated using the DUD-E server⁴⁶. The models were then ranked on the basis of their adjusted logAUC. The selected best scoring model in terms of ligand enrichment was further optimized through minimization with the AMBER protein force field and the GAFF ligand force field supplemented with AM1BCC charges⁴⁷.

Molecular docking of risperidone


Risperidone was docked to the orthosteric binding site of the DRD2 homology models based on the DRD3 or DRD4 crystal structures, using DOCK3.7⁴⁴. DOCK3.7 places pre-generated flexible ligands into the binding site by superimposing atoms of each molecule on matching spheres, representing favorable positions for individual ligand atoms. Forty-five matching spheres were used here, based on the pose of the corresponding x-ray ligand (eticlopride/nemonapride) in the template structure. The resulting docked ligand poses were scored by summing the receptor-ligand electrostatics and van der Waals interaction energies, and corrected for context-dependent ligand desolvation. Receptor structures were protonated using Reduce⁴⁸. Partial charges from the united-atom AMBER⁴⁷ force field were used for all receptor atoms. Grids which evaluate the different energy terms of the DOCK scoring function were precalculated using AMBER⁴⁷ for the van der Waals term, QNIFFT^{49,50} (an

adaptation of DELPHI) for electrostatics, and ligand desolvation⁵¹. Ligands were protonated with Marvin (version 15.11.23.0, ChemAxon, 2015; <http://www.chemaxon.com>), at pH 7.4. Each protomer was rendered into 3D using Corina⁵² (Molecular Networks GmbH) and conformationally sampled using Omega⁵³ (OpenEye Scientific Software). Ligand charges and initial solvation energies were calculated using AMSOL^{54,55}.

Data availability

Atomic coordinates and structure factor files for the DRD2/Risperidone structure have been deposited in the RCSB Protein Data Bank with identification code 6C38. All other data are available from the corresponding authors upon reasonable request.


Extended Data



Extended Data Figure 1. Thermo-stability of DRD2 constructs, crystal packing of the DRD2/Risperidone complex and representative electron density of the DRD2 structure

a, DRD2 or thermo-stability mutation membrane with 1nM [³H]-N-methylspiperone were heated for 30 min, the amount of [³H]-ligand bound determined. **b**, Purified DRD2-T4L (with or without thermo-stability mutation) protein with 10 μ M risperidone and 1 μ M BODIPY FL L-cystine dye were heated by a temperature gradient and the amount of dye bound to unfolding protein determined. Data were analyzed by nonlinear regression and


apparent T_m values (transition temperature where 50% of the receptor is inactive) were determined from analysis of the sigmoidal dose-response curves. All data in **a-b** are the mean \pm SEM of three independent assays. Error bars in **a-b** denote SEM from three independent assays. **c, d, e**, Packing of the DRD2/Risperidone complex crystallized in the $P2_12_12_1$ spacegroup. The DRD2 is shown in green and T4L fusion protein is shown in red or cyan (interact with DRD2). EL_1 and EL_2 of DRD2 were shown in magenta and blue, respectively. **f**, 2Fo-Fc electron density map (blue mesh) of risperidone (yellow) contoured at 1σ . **g**, Fo-Fc omit map (green mesh) contoured at 3.0σ of risperidone (yellow). **h**, 2Fo-Fc electron density map of DRD2 binding pocket residues (blue mesh) contoured at 1σ .



Extended Data Figure 2. Conserved hydrophobic residue of EL₂ in all available aminergic receptor structures

In all panels, receptors are shown as cartoon. Ligands and residues are shown as sticks. **a**, 5HT1B (PDB code 4IAR). **b**, 5HT2B (PDB code 5TVN). **c**, DRD2. **d**, DRD3 (PDB code 3PBL). **e**, DRD4 (PDB code 5WIU). **f**, ACM1 (PDB code 5CXV). **g**, ACM2 (PDB code 3UON). **h**, ACM3 (PDB code 4ADJ). **i**, ACM4 (PDB code 4DSG). **j**, HRH1 (PDB code 3RZE). **k**, ADRB1 (PDB code 2VT4). **l**, ADRB2 (PDB code 2RH1). **m**, DRD2. **n**, Conserved EL₂ hydrophobic residues (red box) are located two residues away from


conserved cysteine that forms a disulfide bridge between EL₂ and helix III. Notable exceptions to the presence of a hydrophobic residue are DRD1 and DRD5, which contain a serine, and HRH1 and HRH4, which contain a threonine and proline, respectively.



Extended Data Figure 3. Comparison of D2 receptors view from the extracellular side and structural alignment with the β_2 adrenergic receptor (β_2 AR) and A_{2A} adenosine (A_{2A} AR) reveals inactive-state of the DRD2


In a-d panels, the DRD2 colored in green; DRD3 in magenta (PDB code 3PBL), and DRD4 in blue (PDB code 5WIU). Risperidone (yellow), eticlopride (cyan) and nemonapride

(lightpink) are shown sticks and spheres. **a, b, c**, Displacements of H^{6.55} and Y/V^{7.35} are shown at DRD2 (a), DRD3 (b) and DRD4 (c). **d**, The views from extracellular side of DRD2 and DRD3. **e, f**, Superposition of TM VI at DRD2 (green), inactive β_2 AR (yellow) (PDB code: 2RH1), active β_2 AR (lightpink) (PDB code: 3SN6), inactive A_{2A}AR (brown) (PDB code: 3REY) and active A_{2A}AR (blue) (PDB code: 5G53) aligned through helices I-IV. **g, h, i, j**, Cytoplasmic view of an alignment between DRD2 and active/inactive β_2 AR (**g, h**) or A_{2A}AR (**i, j**). Rearrangements of two highly conserved residues (Y^{7.53} and R^{3.50}) within the core of the receptor are shown as sticks. Ligands are omitted for clarity, hydrogen bonds are shown as grey dotted line and the Ballesteros-Weinstein numbering is shown as superscript.




Extended Data Figure 4. Conserved Trp of EL₁ in all available aminergic receptor structures illustrates unique position in DRD2/risperidone

In all panels, receptors are shown as cartoon. Ligands and residues are shown as sticks. **a**, Conserved Trp of EL₁ was show in red box. **b**, 5HT1B (PDB code 4IAR). **c**, 5HT2B (PDB code 5TVN). **d**, DRD2. **e**, DRD3 (PDB code 3PBL). **f**, DRD4 (PDB code 5WIU). **g**, ACM1 (PDB code 5CXV). **h**, ACM2 (PDB code 3UON). **i**, ACM3 (PDB code 4ADJ). **j**, ACM4 (PDB code 4DSG). **k**, HRH1 (PDB code 3RZE). **l**, ADRB1 (PDB code 2VT4). **m**, ADRB2 (PDB code 2RH1).



Extended Data Figure 5. Risperidone has distinct poses in solution and in complex with DRD2 and comparison of x-ray structure and model of DRD2

a, Trp100^{EL1} determines the configuration of the tetrahydropyridopyrimidinone moiety of risperidone. Structure of unbound risperidone colored in green and DRD2-bound risperidone in yellow. **b**, Electron density (2Fo-Fc maps, blue mesh) for W100^{EL1} in the DRD2/Risperidone complex (contoured at 1.0 σ). **c**, 2Fo-Fc electron density map (blue mesh) of Leu94^{2,64}, Trp100^{EL1}, Ile184^{EL2} and risperidone (yellow) contoured at 0.8 σ . Ballesteros-Weinstein numbering is shown as superscript. **d**, Overall view of DRD2/Risperidone x-ray structure and model. **e, f, g, h**, Comparison of x-ray structure and model of DRD2. In **d-h** panels, DRD2 x-ray structure and model is shown as cartoons, with the x-ray structure colored in green and model in magenta or blue. Risperidone in x-ray structure is shown as yellow spheres or sticks and model as cyan or lightpink.



Extended Data Figure 6. Patch residues of the DRD2 orthosteric pocket impair the dissociation rates of risperidone, aripiprazole, N-methylspiperone and nemonapride

a, b, c, e, f, g. Comparison of risperidone dissociation from wild-type DRD2 (**a**) and W100^{EL1}A (**b**), W100^{EL1}L (**c**), W100^{EL1}F (**d**), L94^{2.64}A (**e**), I184^{EL2}A (**f**) or L94^{2.64}A / I184^{EL2}A (**g**) mutants. **h, i, j, k, l, m, n.** Comparison of aripiprazole dissociation from wild-type DRD2 (**h**) and W100^{EL1}A (**i**), W100^{EL1}L (**j**), W100^{EL1}F (**k**), L94^{2.64}A (**l**), I184^{EL2}A (**m**) or L94^{2.64}A / I184^{EL2}A (**n**) mutants. **o, p.** Comparison of N-methylspiperone (**o**) or nemonapride (**p**) dissociation from wild-type DRD2 and W100^{EL1}A, W100^{EL1}L or

W100^{EL1F} mutants(n=3). **q**, **r**, Comparison of N-methylspiperone (**q**) or nemonapride (**r**) dissociation from wild-type DRD2 and L94^{2.64}A, I184^{EL2}A or L94^{2.64}A /I184^{EL2}A mutants. All data are the mean \pm SEM of four independent assays (n = 4 independent experiments). Error bars in **o-r** denote SEM from four independent assays. Ballesteros-Weinstein numbering is shown as superscript.

Extended Data Table 1
Affinities of antipsychotic drugs for thermostabilized mutant and wild-type RDR2

Data represent mean K_i ($pK_i \pm$ SEM) for competition binding experiments using [³H]-N-methylspiperone (0.8–1.0 nM) as radioligand. All data are the mean \pm SEM of three independent assays (n = 3 independent experiments).

Receptor K_i , nM ($pK_i \pm$ SEM)	Risperidone	Aripiprazole	N-Methylspiperone	Nemonapride	Bifeprunox
DRD2 wild-type	1.91 (8.84 \pm 0.19)	6.28 (8.21 \pm 0.05)	0.04 (11.06 \pm 0.18)	0.03 (11.06 \pm 0.10)	1.04 (9.52 \pm 0.38)
DRD2 I122 ^{3.40} A/L375 ^{6.37} A/L379 ^{6.41} A	1.86 (9.10 \pm 0.38)	1.25 (8.91 \pm 0.04)	0.09 (11.01 \pm 0.11)	0.05 (11.03 \pm 0.06)	0.24 (9.62 \pm 0.02)
DRD2-T4L(Sf9) I122 ^{3.40} A/L375 ^{6.37} A/L379 ^{6.41} A	3.13 (8.57 \pm 0.18)	1.88 (8.73 \pm 0.02)	0.06 (11.02 \pm 0.04)	0.09 (11.03 \pm 0.33)	0.57 (9.25 \pm 0.03)

Extended Data Table 2
Data collection and refinement statistics

Highest resolution shell is shown in parentheses.

Structure	Human DRD2 (N/ ICL3 _{T4L} / C)-Risperidone complex
Data Collection	APS, GMCA/CAT 23ID-B/D, 10 μ m microfocus beam
Crystals	20
Resolution range	30.00 - 2.90 (2.99 - 2.90)
Space group	P2 ₁ 2 ₁ 2 ₁
Unit cell Dimensions a, b, c (Å)	50.98 72.52 151.31
Unique reflections	12826 (889)
Multiplicity	5.5 (2.5)
Completeness (%)	97.3 (86.9)
Mean 1/ σ (I)	15.2 (1.0)
R _{merge} (%)	13.4 (73.8)
CC _{1/2} (%)	99.4 (53.5)
Refinement Statistics	
Reflections used in refinement	12826 (889)
Reflections used for R-free	622 (40)
R-work (%)	22.6 (37.4)
R-free (%)	24.9 (34.1)
Number of Atoms	
DRD2	1948

Structure	Human DRD2 (N/ ICL3 _{T4L} / C)-Risperidone complex
T4L	1176
Risperidone	30
Lipid and other	82
Overall B-factors (Å²)	
Receptor	84.1
T4L	97
Risperidone	75.8
Lipids, water, other	86.8
Model Statistics	
RMSD-bonds (Å)	0.004
RMSD-angles (°)	0.56
Ramachandran favored (%) [#]	97.36
Ramachandran allowed (%) [#]	2.64
Ramachandran outliers (%) [#]	000
Rotamer outliers (%) [#]	0.67
Clashscore [*]	399

^{*} $R_{\text{merge}} = \sum hkl |I(hkl) - \langle I(hkl) \rangle| / \sum hkl I(hkl)$, where $\langle I(hkl) \rangle$ is the mean of the symmetry equivalent reflections of $I(hkl)$.

[#] As defined in MolProbity.

Extended Data Table 3 Affinity of risperidone and nemonapride at ligand binding pocket mutants of the D₂ dopamine receptor

Data represent mean K_i ($pK_i \pm \text{SEM}$) for competition binding experiments and K_d ($pK_d \pm \text{SEM}$) for homologous competition binding experiments using [³H]-nemonapride (0.1–0.5 nM) as radioligand. All data are the mean $\pm \text{SEM}$ of three independent assays ($n = 3$ independent experiments).

Receptor	Risperidone		Nemonapride	
	K_i , nM ($pK_i \pm \text{SEM}$)	pK_i (mutant-WT)	K_d , nM ($pK_d \pm \text{SEM}$)	pK_d (mutant-WT)
DRD2 wild-type	4.50 (8.41 \pm 0.07)	–	0.21 (9.69 \pm 0.06)	
DRD2 W100 ^{EL1} A	8.14 (8.19 \pm 0.13)	–0.21	1.97 (8.71 \pm 0.02)	–0.98
DRD2 F110 ^{3,28} A	36.89 (7.48 \pm 0.09)	–0.93	0.17 (9.77 \pm 0.03)	0.08
DRD2 D114 ^{3,32} A	>10000	–	8.10 (8.09 \pm 0.04)	–1.60
DRD2 V115 ^{3,33} A	3.07 (8.52 \pm 0.04)	0.11	0.84 (9.08 \pm 0.02)	–0.61
DRD2 C118 ^{3,36} A	4.84 (8.32 \pm 0.01)	–0.09	0.40 (9.40 \pm 0.02)	–0.29
DRD2 T119 ^{3,37} A	177.19 (6.83 \pm 0.12)	–1.58	0.43 (9.38 \pm 0.06)	–0.31
DRD2 I122 ^{3,40} A	13.87 (7.97 \pm 0.13)	–0.44	0.30 (9.52 \pm 0.01)	–0.17

Receptor	Risperidone		Nemonapride	
	K _i , nM (pK _i ± SEM)	pK _i (mutant-WT)	K _d , nM (pK _d ± SEM)	pK _d (mutant-WT)
DRD2 S197 ^{5.46} A	1.22 (8.92 ± 0.03)	0.51	043 (9.37 ± 0.01)	-0.32
DRD2 F198 ^{5.47} A	41.95 (7.38 ± 0.03)	-1.02	0.76 (9.12 ± 0.02)	-0.57
DRD2 F382 ^{6.44} A	57.70 (7.25 ± 0.05)	-1.16	030 (9.53 ± 0.05)	-0.16
DRD2 W386 ^{6.48} A	>10000	-	402 (8.40 ± 0.04)	-1.29
DRD2 F389 ^{6.51} A	2992 (5.65 ± 0.17)	-2.76	4.70 (8.35 ± 0.08)	-1.34
DRD2 F390 ^{6.52} A	31.20 (7.61 ± 0.15)	-0.80	1.30 (8.89 ± 0.03)	-0.80
DRD2 Y408 ^{7.35} A	13.63 (7.95 ± 0.13)	-0.46	0.18 (9.76 ± 0.02)	0.07
DRD2 T412 ^{7.39} A	102.68 (7.02 ± 0.08)	-1.77	4.92 (8.33 ± 0.10)	-1.36
DRD2 Y416 ^{7.43} A	2772 (5.61 ± 0.15)	-2.80	088 (9.06 ± 0.01)	-0.63

Extended Data Table 4
Compound dissociation and association rates at wild-type and mutant DRD2

Data were acquired by association and dissociation kinetic experiments conducted in parallel at room temperature using [³H]-N-methylspiperone (0.8–1.0 nM) for Aripiprazole and N-methylspiperone or [³H]-nemonapride (0.8–1.0 nM) for nemonapride. Estimates of k_{off}, k_{on}, and K_d were obtained from four independent experiments. Residence time was calculated as 1/k_{off}. All data are the mean ± SEM of four independent assays (n = 4 independent experiments). Asterisks indicate statistically significant differences between WT and mutant receptors (n.s.=Not significant. p values are indicated, unpaired two-tailed Student's t-test).

Compound	Receptor	Residence Time, min (k _{off} ± SEM) min ⁻¹	k _{on} ± SEM, M ⁻¹ , min ⁻¹	k _{dr} nM (pK _d ± SEM)
Aripiprazole	DRD2 wild-type	154 (0.0065 ± 0.0004)	7.68 × 10 ⁵ ± 4.94 × 10 ⁵	9.43(8.03 ± 0.07)
	DRD2 W100 ^{EL} L1A	15 (0.067 ± 0.015) ^{↓p=0.006}	2.48 × 10 ⁵ ± 6.5 × 10 ⁴	273(6.56 ± 0.02)
	DRD2 W100 ^{EL} L1L	14 (0.071 ± 0.0007) ^{↓p=0.006}	1.89 × 10 ⁵ ± 3.7 × 10 ⁴	387(6.42 ± 0.08)
	DRD2 W100 ^{EL} L1F	26 (0.038 ± 0.007) ^{↓p=0.008}	6.32 × 10 ⁵ ± 8.5 × 10 ⁴	62.8(7.22 ± 0.14)
	DRD2 L94 ^{2.64} A	59 (0.017 ± 0.002) ^{n.s.}	1.23 × 10 ⁶ ± 1.06 × 10 ⁶	49.8(7.56 ± 0.52)

Compound	Receptor	Residence Time, min (k_{off} ± SEM) min^{-1}	k_{on} ± SEM, $\text{M}^{-1}, \text{min}^{-1}$	k_{dr} nM (pK_d ± SEM)
	DRD2 I184 ^{EL2} A	100 (0010 ± 0.001) ^{n.s.}	6.65×10^5 ± 5.1×10^4	15.5(7.81 ± 0.03)
	DRD2 L94 ^{2.64} A/I184 ^{EL2} A	3 (0.32 ± 0.06) ^{↓p=0.005}	2.93×10^6 ± 2.58×10^6	413(6.64 ± 0.52)
N-Methyl spiperone	DRD2 wild-type	250 (0.004 ± 0.0003)	2.34×10^8 ± 6×10^7	0.018(10.75 ± 0.08)
	DRD2 W100 ^{EL1} A	21 (0.048 ± 0.0079) ^{↓p=0.0073}	1.65×10^8 ± 6×10^7	0.31(9.51 ± 0.08)
	DRD2 W100 ^{EL1} L	20 (0.050 ± 0.0064) ^{↓p=0.0072}	1.72×10^8 ± 4×10^7	0.29(9.53 ± 0.03)
	DRD2 W100 ^{EL1} F	38 (0.026 ± 0.00003) ^{↓p=0.0083}	2.08×10^8 ± 5×10^7	0.13(9.89 ± 0.10)
	DRD2 L94 ^{2.64} A	77 (0.013 ± 0.0047) ^{n.s.}	2.08×10^8 ± 4×10^7	0.062(10.21 ± 0.08)
	DRD2 I184 ^{EL2} A	128 (0.0078 ± 0.00004) ^{n.s.}	1.70×10^8 ± 3×10^7	0.048(10.33 ± 0.08)
	DRD2 L94 ^{2.64} A/I184 ^{EL2} A	6 (0.170 ± 0.063) ^{↓p=0.064}	1.62×10^8 ± 1×10^7	1.02(9.01 ± 0.14)
Nemonaptide	DRD2 wild-type	167 (0.006 ± 0.0002)	2.0×10^8 ± 5×10^7	0.031(10.52 ± 0.09)
	DRD2 W100 ^{EL1} A	43 (0.023 ± 0.001) ^{↓p=0.002}	1.17×10^8 ± 2×10^7	0.19(9.75 ± 0.14)
	DRD2 W100 ^{EL1} L	45 (0.022 ± 0.0018) ^{↓p=0.003}	1.07×10^8 ± 3×10^7	0.20(9.70 ± 0.02)
	DRD2 W100 ^{EL1} F	40 (0.025 ± 0.0019) ^{↓p=0.002}	2.03×10^8 ± 6×10^7	0.13(9.90 ± 0.10)
	DRD2 L94 ^{2.64} A	26 (0.039 ± 0.0033) ^{↓p=0.0015}	2.97×10^8 ± 5×10^7	0.13(9.88 ± 0.03)
	DRD2 I184 ^{EL2} A	149 (0.0067 ± 0.0004) ^{n.s.}	9.60×10^7 ± 7×10^6	0.07(10.16 ± 0.06)
	DRD2 L94 ^{2.64} A/I184 ^{EL2} A	5 (0.20 ± 0.0048) ^{↓p=0.0009}	2.89×10^8 ± 1×10^8	0.82(9.12 ± 0.19)

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by NIH Grants RO1MH61887, U19MH82441, the NIMH Psychoactive Drug Screening Program Contract and the Michael Hooker Chair for Protein Therapeutics and Translational Proteomics (to B.L.R.) and by GM59957 (to B.K.S.). We gratefully acknowledge J. Sondek and S. Endo-Streeter for providing independent structure quality control analysis; M. J. Miley and the UNC macromolecular crystallization core for advice and use of their equipment for crystal harvesting and transport, which is supported by the National Cancer Institute under award number P30CA016086; B.E. Krumm for advice on data processing and help with thermostabilization assays, and the staff of GM/CA@APS, which has been funded with Federal funds from the National Cancer Institute (ACB-12002) and the National Institute of General Medical Sciences (AGM-12006). This research used resources of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office of Science User Facility operated for the DOE Office of Science by Argonne National Laboratory under Contract No. DE-AC02-06CH11357.

References

1. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. *Physiol Rev.* 1998; 78:189–225. [PubMed: 9457173]
2. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. *Science.* 1976; 192:481–483. [PubMed: 3854]
3. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin₂ pKi values. *J Pharmacol Exp Ther.* 1989; 251:238–246. [PubMed: 2571717]
4. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. *Nat Rev Drug Discov.* 2004; 3:353–359. [PubMed: 15060530]
5. Roth BL. Drugs and valvular heart disease. *N Engl J Med.* 2007; 356:6–9. [PubMed: 17202450]
6. Seeman P, Lee T. Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. *Science.* 1975; 188:1217–1219. [PubMed: 1145194]
7. Sibley DR, Monsma FJ Jr. Molecular biology of dopamine receptors. *Trends Pharmacol Sci.* 1992; 13:61–69. [PubMed: 1561715]
8. Beaulieu JM, Gainetdinov RR. The physiology, signaling, and pharmacology of dopamine receptors. *Pharmacol Rev.* 2011; 63:182–217. [PubMed: 21303898]
9. Volkow ND, Fowler JS, Wang GJ, Swanson JM, Telang F. Dopamine in drug abuse and addiction: results of imaging studies and treatment implications. *Arch Neurol.* 2007; 64:1575–1579. [PubMed: 17998440]
10. Bunzow JR, et al. Cloning and expression of a rat D2 dopamine receptor cDNA. *Nature.* 1988; 336:783–787. [PubMed: 2974511]
11. Grandy DK, et al. Cloning of the cDNA and gene for a human D2 dopamine receptor. *Proc Natl Acad Sci U S A.* 1989; 86:9762–9766. [PubMed: 2532362]
12. Monsma FJ Jr, McVittie LD, Gerfen CR, Mahan LC, Sibley DR. Multiple D2 dopamine receptors produced by alternative RNA splicing. *Nature.* 1989; 342:926–929. [PubMed: 2480527]
13. Allen JA, et al. Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy. *Proc Natl Acad Sci U S A.* 2011; 108:18488–18493. [PubMed: 22025698]
14. Javitch JFD, Chen J, Karlin A. Mapping the binding-site crevice of the dopamine D2 receptor by the substituted-cysteine accessibility method. *Neuron.* 1995; 14:825–831. [PubMed: 7718244]
15. Ballesteros JA, Shi L, Javitch JA. Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. *Mol Pharmacol.* 2001; 60:1–19. [PubMed: 11408595]
16. Chien EY, et al. Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. *Science.* 2010; 330:1091–1095. [PubMed: 21097933]
17. Wang S, et al. D4 dopamine receptor high-resolution structures enable the discovery of selective agonists. *Science.* 2017; 358:381–386. [PubMed: 29051383]
18. Manglik A, et al. Structure-based discovery of opioid analgesics with reduced side effects. *Nature.* 2016; 537:185–190. [PubMed: 27533032]
19. Wacker D, Stevens RC, Roth BL. How Ligands Illuminate GPCR Molecular Pharmacology. *Cell.* 2017; 170:414–427. [PubMed: 28753422]
20. McCorvy JD, et al. Structure-inspired design of beta-arrestin-biased ligands for aminergic GPCRs. *Nat Chem Biol.* (in press).
21. Free RB, et al. Discovery and characterization of a G protein-biased agonist that inhibits beta-arrestin recruitment to the D2 dopamine receptor. *Mol Pharmacol.* 2014; 86:96–105. [PubMed: 24755247]
22. Roberts DJ, Strange PG. Mechanisms of inverse agonist action at D2 dopamine receptors. *Br J Pharmacol.* 2005; 145:34–42. [PubMed: 15735658]
23. Rasmussen SG, et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. *Nature.* 2011; 477:549–555. [PubMed: 21772288]

24. Shapiro DA, Kristiansen K, Weiner DM, Kroeze WK, Roth BL. Evidence for a model of agonist-induced activation of 5-HT_{2A} serotonin receptors which involves the disruption of a strong ionic interaction between helices 3 and 6. *J Biol Chem.* 2002; 18:18.
25. Ballesteros JA, et al. Activation of the beta 2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6. *J Biol Chem.* 2001; 276:29171–29177. [PubMed: 11375997]
26. Palczewski K, et al. Crystal structure of rhodopsin: A G protein-coupled receptor. *Science.* 2000; 289:739–745. [PubMed: 10926528]
27. Janssen PA, et al. Pharmacology of risperidone (R 64,766) a new antipsychotic with serotonin-5₂ and dopamine-D₂ antagonistic properties. *Journal of Pharmacology and Experimental Therapeutics.* 1988; 244:685–693. [PubMed: 2450200]
28. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. *Am J Psychiatry.* 2000; 157:514–520. [PubMed: 10739409]
29. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. *Am J Psychiatry.* 2001; 158:360–369. [PubMed: 11229973]
30. Sykes DA, et al. Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D₂ receptors. *Nat Commun.* 2017; 8:763. [PubMed: 28970469]
31. Monsma FJ Jr, McVittie LD, Gerfen CR, Mahan LC, Sibley DR. Multiple D₂ dopamine receptors produced by alternative RNA splicing. *Nature.* 1989; 342:926–929. [PubMed: 2480527]
32. Rosenbaum DM, et al. GPCR engineering yields high-resolution structural insights into beta₂-adrenergic receptor function. *Science.* 2007; 318:1266–1273. [PubMed: 17962519]
33. Caffrey M, Cherezov V. Crystallizing membrane proteins using lipidic mesophases. *Nat Protoc.* 2009; 4:706–731. [PubMed: 19390528]
34. Minor W, Cymborowski M, Otwinowski Z, Chruszcz M. HKL-3000: the integration of data reduction and structure solution—from diffraction images to an initial model in minutes. *Acta Crystallogr D Biol Crystallogr.* 2006; 62:859–866. [PubMed: 16855301]
35. McCoy AJ, et al. Phaser crystallographic software. *J Appl Crystallogr.* 2007; 40:658–674. [PubMed: 19461840]
36. Adams PD, et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. *Acta crystallographica Section D, Biological crystallography.* 2010; 66:213–221. [PubMed: 20124702]
37. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. *Acta Crystallogr D Biol Crystallogr.* 2010; 66:486–501. [PubMed: 20383002]
38. Allen JA, et al. Discovery of beta-arrestin-biased dopamine D₂ ligands for probing signal transduction pathways essential for antipsychotic efficacy. *Proc Natl Acad Sci U S A.* 2011; 108:18488–18493. [PubMed: 22025698]
39. Motulsky HJ, Mahan LC. The kinetics of competitive radioligand binding predicted by the law of mass action. *Mol Pharmacol.* 1984; 25:1–9. [PubMed: 6708928]
40. Pei J, Grishin NV. PROMALS3D: multiple protein sequence alignment enhanced with evolutionary and three-dimensional structural information. *Methods Mol Biol.* 2014; 1079:263–271. [PubMed: 24170408]
41. Chien EY, et al. Structure of the human dopamine D₃ receptor in complex with a D₂/D₃ selective antagonist. *Science.* 2010; 330:1091–1095. [PubMed: 21097933]
42. Wang S, et al. D₄ dopamine receptor high-resolution structures enable the discovery of selective agonists. *Science.* 2017; 358:381–386. [PubMed: 29051383]
43. Webb B, Sali A. Comparative Protein Structure Modeling Using MODELLER. *Curr Protoc Bioinformatics.* 2014; 47:561–5632.
44. Coleman RG, Carchia M, Sterling T, Irwin JJ, Shoichet BK. Ligand pose and orientational sampling in molecular docking. *PLoS One.* 2013; 8:e75992. [PubMed: 24098414]
45. Southan C, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. *Nucleic Acids Res.* 2016; 44:D1054–1068. [PubMed: 26464438]

46. Mysinger MM, Carchia M, Irwin JJ, Shoichet BK. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. *J Med Chem.* 2012; 55:6582–6594. [PubMed: 22716043]
47. Case DA, et al. AMBER. 2015; 2015
48. Word JM, Lovell SC, Richardson JS, Richardson DC. Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation1. *Journal of Molecular Biology.* 1999; 285:1735–1747. [PubMed: 9917408]
49. Gallagher K, Sharp K. Electrostatic contributions to heat capacity changes of DNA-ligand binding. *Biophys J.* 1998; 75:769–776. [PubMed: 9675178]
50. Sharp KA. Polyelectrolyte electrostatics: Salt dependence, entropic, and enthalpic contributions to free energy in the nonlinear Poisson–Boltzmann model. *Biopolymers.* 1995; 36:227–243.
51. Mysinger MM, Shoichet BK. Rapid context-dependent ligand desolvation in molecular docking. *J Chem Inf Model.* 2010; 50:1561–1573. [PubMed: 20735049]
52. Sadowski J, Gasteiger J, Klebe G. Comparison of Automatic Three-Dimensional Model Builders Using 639 X-ray Structures. *Journal of Chemical Information and Computer Sciences.* 1994; 34:1000–1008.
53. Hawkins PC, Skillman AG, Warren GL, Ellingson BA, Stahl MT. Conformer generation with OMEGA: algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database. *J Chem Inf Model.* 2010; 50:572–584. [PubMed: 20235588]
54. Chambers CC, Hawkins GD, Cramer CJ, Truhlar DG. Model for Aqueous Solvation Based on Class IV Atomic Charges and First Solvation Shell Effects. *The Journal of Physical Chemistry.* 1996; 100:16385–16398.
55. Li J, Zhu T, Cramer CJ, Truhlar DG. New Class IV Charge Model for Extracting Accurate Partial Charges from Wave Functions. *The Journal of Physical Chemistry A.* 1998; 102:1820–1831.




Figure 1. Structural details of DRD2 and comparison with DRD3 and DRD4

In all panels, dopamine receptor structures are shown aligned to the DRD2, with the DRD2 colored in green; DRD3 in magenta (PDB code 3PBL), and DRD4 in blue (PDB code 5WIU). Risperidone (yellow) is shown in sphere representation. **a**, Overall structure of the DRD2/Risperidone complex. **b**, **c**, Comparison of the view from the extracellular side. **d**, Cytoplasmic surface showing salt-bridge interaction (grey dotted line) between R132^{3.50} and E368^{6.30}. In all panels, the Ballesteros-Weinstein numbering is shown as superscript.




Figure 2. Comparison of the ligand binding pocket across the D₂-like family receptors
a, b, c, Surface representations of the ligand binding pockets of DRD2 (**a**), DRD3 (**b**) (PDB code 3PBL) and DRD4 (**c**) (PDB code 5WIU) are shown in transparent gray. **d,** A schematic representation of risperidone binding interactions at a 4.0 Å cut-off is shown. Hydrogen bonds are shown in grey dashed lines. Mutations of the amino acid in the red boxes reduces risperidone binding affinity by more than tenfold. The thermo-stabilizing mutation (I122^{3,40}A) colored in blue. The outline of deeper hydrophobic pocket is colored as orange.




Figure 3. Different extended binding pockets revealed across D₂-like family receptors
a, The distinctive selective extended binding pocket (EBP) defined by four key residues in the D₂-like family receptors are delineated. The residues of DRD2 (green), DRD3 (pink) (PDB code 3PBL) and DRD4 (blue) (PDB code 5WIU) are shown as sticks. **b**, **c**, **d**, Structural differences in the EBPs of DRD2 (**b**), DRD3 (**c**) and DRD4 (**d**) are evident. Residues and ligands are colored as in (**a**). The position of each EBP is shown as an ellipse with the Ballesteros-Weinstein numbering as superscript.




Figure 4. The hydrophobic “patch” of the DRD2 binding pocket
a, Risperidone (yellow) bound to DRD2 (green) orthosteric pocket viewed from extracellular space. **b**, The W100^{EL1} side chain forms extensive hydrophobic contacts with residues L94^{2.64} and I184^{EL2}. **c**, The residues L94^{2.64}, W100^{EL1} and I184^{EL2} form a patch (red, with other residues in grey) that narrows DRD2’s binding pocket.

Table 1

Risperidone dissociation and association rates at wild-type and mutant DRD2.

Receptor	Residence Time, min ($k_{\text{off}} \pm \text{SEM}$) min^{-1}	$k_{\text{on}} \pm \text{SEM}$, $\text{M}^{-1} \text{min}^{-1}$	K_{d} , nM ($\text{p}K_{\text{d}} \pm \text{SEM}$)
DRD2 wild-type	233 (0.0043 \pm 0.0003)	$1.65 \times 10^6 \pm 1.7 \times 10^5$	2.51 (8.65 \pm 0.21)
DRD2 W100 ^{EL1} A	28 (0.036 \pm 0.0022)* $p=0.007$	$5.63 \times 10^6 \pm 3.2 \times 10^5$	6.74 (8.17 \pm 0.04)
DRD2 W100 ^{EL1} L	23 (0.043 \pm 0.004) * $p=0.06$	$6.32 \times 10^6 \pm 5.5 \times 10^5$	6.77 (8.17 \pm 0.002)
DRD2 W100 ^{EL1} F	59 (0.017 \pm 0.002) * $p=0.01$	$3.12 \times 10^6 \pm 1.8 \times 10^5$	5.30 (8.28 \pm 0.02)
DRD2 L94 ^{2,64} A	139 (0.0072 \pm 0.0029) ^{n.s.}	$1.43 \times 10^7 \pm 2.3 \times 10^6$	0.48 (9.33 \pm 0.12)
DRD2 I184 ^{EL2} A	185 (0.0054 \pm 0.002) ^{n.s.}	$9.84 \times 10^6 \pm 1.4 \times 10^6$	0.54 (9.28 \pm 0.10)
DRD2 L94 ^{2,64} A/I184 ^{EL2} A	6 (0.16 \pm 0.05) * $p=0.005$	$2.36 \times 10^7 \pm 7.8 \times 10^6$	7.01 (8.15 \pm 0.02)

Data were acquired by association and dissociation kinetic experiments conducted in parallel at room temperature using [³H]-N-methylspiperone (0.8–1.0 nM). Estimates of k_{off} , k_{on} , and K_{d} were obtained from four independent experiments. Residence time was calculated as $1/k_{\text{off}}$. All data are the mean \pm

SEM of four independent assays (n = 4 independent experiments). Asterisks indicate statistically significant differences between WT and mutant receptors (n.s.=Not significant, p values are indicated, unpaired two-tailed Student's t-test).